Our vision is to improve the treatment of severe diseases. Working with the medicines of the future we focus on oncology.

Research and Development

Human HealthOasmia is development the next generation of drugs with focus on oncology.

Further reading »

About Oasmia

Animal HealthOasmia is a pharmaceutical company in Uppsala, Sweden with one approved product in Russia and one conditionally approved in the USA.

Further reading »

The Share

Latest News

Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ)

April 29 2016
Further reading »

Oasmia Pharmaceutical Announces Positive Overall Survival Results from Phase III Study of Paclical/Apealea for Treatment of Ovarian Cancer

April 27 2016
Overall Survival data from the Phase III study meets endpoint and demonstrates non-inferiority favoring Paclical/Apealea; will form basis for application seeking marketing approval in the United States anticipated for the end of 2016/2017.
Further reading »

Oasmia successfully completes private placements of new convertible instruments and new shares in the total amount of SEK 45,5 million

April 15 2016
Uppsala, Sweden, April 15, 2016 -- Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 28,000,000 with an interest rate of 8.5 per cent per year, as well as 1,666,666 new shares directed to and placed with institutional and qualified investors in Sweden (the “Private Placements”). The convertible instrument issue is expected to provide the Company with SEK 28,000,000 and the new share issue SEK 17,500,000 before transaction related costs.
Further reading »